

Michael John Gill

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6485364/publications.pdf>

Version: 2024-02-01

174
papers

11,361
citations

41344

49
h-index

30087

103
g-index

175
all docs

175
docs citations

175
times ranked

11876
citing authors

#	ARTICLE	IF	CITATIONS
1	Do contemporary antiretrovirals increase the risk of end-stage liver disease? Signals from patients starting therapy in the North American AIDS Cohort Collaboration on Research and Design. <i>Pharmacoepidemiology and Drug Safety</i> , 2022, 31, 214-224.	1.9	3
2	Five-Year Mortality for Adults Entering Human Immunodeficiency Virus Care Under Universal Early Treatment Compared With the General US Population. <i>Clinical Infectious Diseases</i> , 2022, 75, 867-874.	5.8	10
3	Virologic outcomes among adults with HIV using integrase inhibitor-based antiretroviral therapy. <i>Aids</i> , 2022, 36, 277-286.	2.2	5
4	Longitudinal analysis of HIV outcomes for persons living with HIV in non-urban areas in southern Alberta, Canada. <i>Jammi</i> , 2022, 7, 44-53.	0.5	0
5	CD4/CD8 Ratio and Cancer Risk Among Adults With HIV. <i>Journal of the National Cancer Institute</i> , 2022, 114, 854-862.	6.3	26
6	Timing of Antiretroviral Therapy Initiation and Risk of Cancer Among Persons Living With Human Immunodeficiency Virus. <i>Clinical Infectious Diseases</i> , 2021, 72, 1900-1909.	5.8	22
7	Longitudinal evaluation of risk factors and outcomes of blood stream infections due to <i>Staphylococcus</i> species in persons with HIV: An observational cohort study. <i>EClinicalMedicine</i> , 2021, 31, 100675.	7.1	1
8	Trends in Hepatocellular Carcinoma Incidence and Risk Among Persons With HIV in the US and Canada, 1996-2015. <i>JAMA Network Open</i> , 2021, 4, e2037512.	5.9	26
9	Predictive variables for peripheral neuropathy in treated HIV type 1 infection revealed by machine learning. <i>Aids</i> , 2021, 35, 1785-1793.	2.2	4
10	Secular Trends in Breast Cancer Risk Among Women With HIV Initiating ART in North America. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2021, 87, 663-670.	2.1	3
11	Plasma microRNAs are associated with domain-specific cognitive function in people with HIV. <i>Aids</i> , 2021, 35, 1795-1804.	2.2	1
12	Association of the VACS Index with hospitalization among people with HIV in the NA-ACCORD. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2021, Publish Ahead of Print, 9-18.	2.1	1
13	Reconstructing SARS-CoV-2 infection dynamics through the phylogenetic inference of unsampled sources of infection. <i>PLoS ONE</i> , 2021, 16, e0261422.	2.5	4
14	Association of Immunosuppression and Human Immunodeficiency Virus (HIV) Viremia With Anal Cancer Risk in Persons Living With HIV in the United States and Canada. <i>Clinical Infectious Diseases</i> , 2020, 70, 1176-1185.	5.8	27
15	Machine learning models reveal neurocognitive impairment type and prevalence are associated with distinct variables in HIV/AIDS. <i>Journal of NeuroVirology</i> , 2020, 26, 41-51.	2.1	16
16	Evaluating medical conferences: the emerging need for a quality metric. <i>Scientometrics</i> , 2020, 122, 759-764.	3.0	8
17	In Defense of Baseline Genotypic Antiretroviral Resistance Testing. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2020, 83, e1-e2.	2.1	2
18	Identification and root cause analysis of aberrant CD4+ cell counts in an HIV cohort: the importance of quality control in changing laboratory procedure. <i>Aids</i> , 2020, 34, 1869-1873.	2.2	0

#	ARTICLE	IF	CITATIONS
19	Clinical Effectiveness of Integrase Strand Transfer Inhibitor-Based Antiretroviral Regimens Among Adults With Human Immunodeficiency Virus: A Collaboration of Cohort Studies in the United States and Canada. <i>Clinical Infectious Diseases</i> , 2020, 73, e1408-e1414.	5.8	6
20	Lifetime antiretroviral exposure and neurocognitive impairment in HIV. <i>Journal of NeuroVirology</i> , 2020, 26, 743-753.	2.1	26
21	HIV diagnosed after 50 years of age. <i>Cmaj</i> , 2020, 192, E255-E255.	2.0	3
22	Schistosoma and Strongyloides screening in migrants initiating HIV Care in Canada: a cross sectional study. <i>BMC Infectious Diseases</i> , 2020, 20, 76.	2.9	3
23	Evaluation of A Phylogenetic Pipeline to Examine Transmission Networks in A Canadian HIV Cohort. <i>Microorganisms</i> , 2020, 8, 196.	3.6	7
24	Transmission of human immunodeficiency virus (HIV) to a family caregiver through a conjunctival blood splash. <i>Infection Control and Hospital Epidemiology</i> , 2020, 41, 742-744.	1.8	1
25	Life-Expectancy Disparities Among Adults With HIV in the United States and Canada: The Impact of a Reduction in Drug- and Alcohol-Related Deaths Using the Lives Saved Simulation Model. <i>American Journal of Epidemiology</i> , 2019, 188, 2097-2109.	3.4	32
26	Association of immunosuppression and HIV viraemia with non-Hodgkin lymphoma risk overall and by subtype in people living with HIV in Canada and the USA: a multicentre cohort study. <i>Lancet HIV</i> , 2019, 6, e240-e249.	4.7	46
27	Protecting the health of children moving to Canada. <i>Lancet, The</i> , 2019, 394, 1901-1902.	13.7	1
28	Effect of incident hepatitis C infection on CD4+ cell count and HIV RNA trajectories based on a multinational HIV seroconversion cohort. <i>Aids</i> , 2019, 33, 327-337.	2.2	5
29	An approach to conference selection and evaluation: advice to avoid "predatory" conferences. <i>Scientometrics</i> , 2019, 118, 687-698.	3.0	14
30	Empiric neurocognitive performance profile discovery and interpretation in HIV infection. <i>Journal of NeuroVirology</i> , 2019, 25, 72-84.	2.1	16
31	An Emerging Concern "High Rates of Frailty among Middle-aged and Older Individuals Living with HIV. <i>Canadian Geriatrics Journal</i> , 2019, 22, 190-198.	1.2	9
32	Multimorbidity Among Persons Living with Human Immunodeficiency Virus in the United States. <i>Clinical Infectious Diseases</i> , 2018, 66, 1230-1238.	5.8	131
33	Increasing incidence of syphilis among patients engaged in HIV care in Alberta, Canada: a retrospective clinic-based cohort study. <i>BMC Infectious Diseases</i> , 2018, 18, 125.	2.9	16
34	Associations between Depressive Symptomatology and Neurocognitive Impairment in HIV/AIDS. <i>Canadian Journal of Psychiatry</i> , 2018, 63, 329-336.	1.9	21
35	Identifying Risk of Viral Failure in Treated HIV-Infected Patients Using Different Measures of Adherence: The Antiretroviral Therapy Cohort Collaboration. <i>Journal of Clinical Medicine</i> , 2018, 7, 328.	2.4	4
36	Managing HIV infection in patients older than 50 years. <i>Cmaj</i> , 2018, 190, E1253-E1258.	2.0	12

#	ARTICLE	IF	CITATIONS
37	Combating the HIV reservoirs. <i>Biotechnology and Genetic Engineering Reviews</i> , 2018, 34, 76-89.	6.2	13
38	Brief Report: Cutaneous Melanoma Risk Among People With HIV in the United States and Canada. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2018, 78, 499-504.	2.1	17
39	A retrospective study of the clinical features of new syphilis infections in an HIV-positive cohort in Alberta, Canada. <i>BMJ Open</i> , 2018, 8, e021544.	1.9	16
40	HIV-associated sensory polyneuropathy and neuronal injury are associated with miRNA-455-3p induction. <i>JCI Insight</i> , 2018, 3, .	5.0	28
41	First occurrence of diabetes, chronic kidney disease, and hypertension among North American HIV-infected adults, 2000-2013. <i>Clinical Infectious Diseases</i> , 2017, 64, ciw804.	5.8	37
42	Survival of HIV-positive patients starting antiretroviral therapy between 1996 and 2013: a collaborative analysis of cohort studies. <i>Lancet HIV</i> , 2017, 4, e349-e356.	4.7	805
43	Comparison of Kaposi Sarcoma Risk in Human Immunodeficiency Virus-Positive Adults Across 5 Continents: A Multiregional Multicohort Study. <i>Clinical Infectious Diseases</i> , 2017, 65, 1316-1326.	5.8	44
44	Healthcare contacts among patients lost to follow-up in HIV care: review of a large regional cohort utilizing electronic health records. <i>International Journal of STD and AIDS</i> , 2017, 28, 1275-1281.	1.1	3
45	HIV misdiagnosis: A root cause analysis leading to improvements in HIV diagnosis and patient care. <i>Journal of Clinical Virology</i> , 2017, 96, 84-88.	3.1	16
46	Evaluating the Impact of Functional Genetic Variation on HIV-1 Control. <i>Journal of Infectious Diseases</i> , 2017, 216, 1063-1069.	4.0	20
47	CD4:CD8 Ratio and CD8 Count as Prognostic Markers for Mortality in Human Immunodeficiency Virus-Infected Patients on Antiretroviral Therapy: The Antiretroviral Therapy Cohort Collaboration (ART-CC). <i>Clinical Infectious Diseases</i> , 2017, 65, 959-966.	5.8	75
48	Cancer-Attributable Mortality Among People With Treated Human Immunodeficiency Virus Infection in North America. <i>Clinical Infectious Diseases</i> , 2017, 65, 636-643.	5.8	67
49	Understanding the delay in starting antiretroviral therapy despite recent guidelines for HIV patients retained in care. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2017, 29, 564-569.	1.2	10
50	Reduced antiretroviral drug efficacy and concentration in HIV-infected microglia contributes to viral persistence in brain. <i>Retrovirology</i> , 2017, 14, 47.	2.0	57
51	Determinants of risk-taking in HIV-associated neurocognitive disorders.. <i>Neuropsychology</i> , 2017, 31, 798-810.	1.3	8
52	A prognostic model for development of significant liver fibrosis in HIV-hepatitis C co-infection. <i>PLoS ONE</i> , 2017, 12, e0176282.	2.5	6
53	A picture is worth a thousand words: maps of HIV indicators to inform research, programs, and policy from NAACCORD and CCASAnet clinical cohorts. <i>Journal of the International AIDS Society</i> , 2016, 19, 20707.	3.0	8
54	HIV Infection, Immunosuppression, and Age at Diagnosis of Non-AIDS-Defining Cancers. <i>Clinical Infectious Diseases</i> , 2016, 64, ciw764.	5.8	63

#	ARTICLE	IF	CITATIONS
55	Montreal Cognitive Assessment Performance in HIV/AIDS: Impact of Systemic Factors. Canadian Journal of Neurological Sciences, 2016, 43, 157-162.	0.5	11
56	Plasma microRNA profiling predicts HIV-associated neurocognitive disorder. Aids, 2016, 30, 2021-2031.	2.2	38
57	Mortality According to CD4 Count at Start of Combination Antiretroviral Therapy Among HIV-infected Patients Followed for up to 15 Years After Start of Treatment: Collaborative Cohort Study. Clinical Infectious Diseases, 2016, 62, 1571-1577.	5.8	52
58	Risk of End-Stage Liver Disease in HIV-Viral Hepatitis Coinfected Persons in North America From the Early to Modern Antiretroviral Therapy Eras. Clinical Infectious Diseases, 2016, 63, ciw531.	5.8	60
59	Incidence of AIDS-Defining Opportunistic Infections in a Multicohort Analysis of HIV-infected Persons in the United States and Canada, 2000-2010. Journal of Infectious Diseases, 2016, 214, 862-872.	4.0	116
60	Mechanisms by Which Interleukin-12 Corrects Defective NK Cell Anticryptococcal Activity in HIV-Infected Patients. MBio, 2016, 7, .	4.1	7
61	How Generalizable Are the Results From Trials of Direct Antiviral Agents to People Coinfected With HIV/HCV in the Real World?. Clinical Infectious Diseases, 2016, 62, 919-926.	5.8	65
62	The Impact of Non-Antiretroviral Polypharmacy on the Continuity of Antiretroviral Therapy (ART) Among HIV Patients. AIDS Patient Care and STDs, 2016, 30, 11-17.	2.5	43
63	Tobacco Smoking Is Not Associated With Accelerated Liver Disease in Human Immunodeficiency Virus-Hepatitis C Coinfection: A Longitudinal Cohort Analysis. Open Forum Infectious Diseases, 2016, 3, ofw050.	0.9	14
64	A Case of Long-Term Seronegative Human Immunodeficiency Virus (HIV) Infection: The Importance of the Humoral Response to HIV. Open Forum Infectious Diseases, 2016, 3, ofv209.	0.9	5
65	Maintaining the continuity of HIV-care records for patients transferring care between centers: challenges, workloads, needs and risks. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2016, 28, 1073-1078.	1.2	5
66	Central nervous system penetration effectiveness of antiretroviral drugs and neuropsychological impairment in the Ontario HIV Treatment Network Cohort Study. Journal of NeuroVirology, 2016, 22, 349-357.	2.1	56
67	Dual Therapy Treatment Strategies for the Management of Patients Infected with HIV: A Systematic Review of Current Evidence in ARV-Naïve or ARV-Experienced, Virologically Suppressed Patients. PLoS ONE, 2016, 11, e0148231.	2.5	70
68	Cause-Specific Mortality in HIV-Positive Patients Who Survived Ten Years after Starting Antiretroviral Therapy. PLoS ONE, 2016, 11, e0160460.	2.5	86
69	Cumulative Incidence of Cancer Among Persons With HIV in North America. Annals of Internal Medicine, 2015, 163, 507-518.	3.9	271
70	Interpersonal Violence and Its Impact on Persons Living With HIV: A Social Work Response. Journal of HIV/AIDS and Social Services, 2015, 14, 308-318.	0.7	4
71	Mortality in migrants with HIV in western Europe. Lancet HIV, 2015, 2, e508-e509.	4.7	0
72	Myocardial Infarction in HIV-Infected Persons: Time to Focus on the Silent Elephant in the Room?. Clinical Infectious Diseases, 2015, 60, 1424-5.	5.8	1

#	ARTICLE	IF	CITATIONS
73	Implementing an Intimate Partner Violence (IPV) Screening Protocol in HIV Care. <i>AIDS Patient Care and STDs</i> , 2015, 29, 133-141.	2.5	19
74	The Impact of Transfer Patients on the Local Cascade of HIV Care Continuum. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2015, 68, 236-240.	2.1	3
75	Decision making under explicit risk is impaired in individuals with human immunodeficiency virus (HIV). <i>Journal of Clinical and Experimental Neuropsychology</i> , 2015, 37, 733-750.	1.3	13
76	End-Stage Renal Disease Among HIV-Infected Adults in North America. <i>Clinical Infectious Diseases</i> , 2015, 60, 941-949.	5.8	142
77	The Cost of Antiretroviral Drug Resistance in HIV-Positive Patients. <i>Antiviral Therapy</i> , 2014, 19, 341-348.	1.0	14
78	Disparities in the Quality of HIV Care When Using US Department of Health and Human Services Indicators. <i>Clinical Infectious Diseases</i> , 2014, 58, 1185-1189.	5.8	65
79	Cohort Profile: Antiretroviral Therapy Cohort Collaboration (ART-CC). <i>International Journal of Epidemiology</i> , 2014, 43, 691-702.	1.9	64
80	Incidence and risk factors of HPV-related and HPV-unrelated Head and Neck Squamous Cell Carcinoma in HIV-infected individuals. <i>Oral Oncology</i> , 2014, 50, 1169-1176.	1.5	77
81	Impact of Risk Factors for Specific Causes of Death in the First and Subsequent Years of Antiretroviral Therapy Among HIV-Infected Patients. <i>Clinical Infectious Diseases</i> , 2014, 59, 287-297.	5.8	136
82	Virological characteristics of occult hepatitis B virus in a North American cohort of human immunodeficiency virus type 1-positive patients on dual active anti-HBV/HIV therapy. <i>Journal of Clinical Virology</i> , 2014, 60, 347-353.	3.1	23
83	Intimate Partner Violence and HIV: A Review. <i>Current HIV/AIDS Reports</i> , 2013, 10, 380-389.	3.1	52
84	Hepatitis C Viremia and the Risk of Chronic Kidney Disease in HIV-Infected Individuals. <i>Journal of Infectious Diseases</i> , 2013, 208, 1240-1249.	4.0	43
85	Trends and Disparities in Antiretroviral Therapy Initiation and Virologic Suppression Among Newly Treatment-Eligible HIV-Infected Individuals in North America, 2001–2009. <i>Clinical Infectious Diseases</i> , 2013, 56, 1174-1182.	5.8	90
86	Influence of Geographical Origin and Ethnicity on Mortality in Patients on Antiretroviral Therapy in Canada, Europe, and the United States. <i>Clinical Infectious Diseases</i> , 2013, 56, 1800-1809.	5.8	28
87	Prevalence, clinical associations, and impact of intimate partner violence among HIV-infected gay and bisexual men: a population-based study. <i>HIV Medicine</i> , 2013, 14, 293-302.	2.2	48
88	Evaluation of brief screening tools for neurocognitive impairment in HIV/AIDS. <i>Aids</i> , 2013, 27, 2385-2401.	2.2	82
89	Invasive Cervical Cancer Risk Among HIV-Infected Women. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2013, 62, 405-413.	2.1	184
90	Gastrointestinal Viral Load and Enteroendocrine Cell Number Are Associated with Altered Survival in HIV-1 Infected Individuals. <i>PLoS ONE</i> , 2013, 8, e75967.	2.5	6

#	ARTICLE	IF	CITATIONS
91	Closing the Gap: Increases in Life Expectancy among Treated HIV-Positive Individuals in the United States and Canada. PLoS ONE, 2013, 8, e81355.	2.5	1,111
92	Durability of first ART regimen and risk factors for modification, interruption or death in HIV-positive patients starting ART in Europe and North America 2002â€“2009. Aids, 2013, 27, 803-813.	2.2	70
93	The Direct Medical Costs of Late Presentation (10^{-7}). J Epidemiol, 2012, 22, 784-789.	0.7	65
94	15-Year Period. AIDS Research and Treatment, 2012, 2012, 1-8.	1.9	34
95	Heterogeneity in outcomes of treated HIV-positive patients in Europe and North America: relation with patient and cohort characteristics. International Journal of Epidemiology, 2012, 41, 1807-1820.	5.8	16
96	Uptake of Combination Antiretroviral Therapy and HIV Disease Progression According to Geographical Origin in Seroconverters in Europe, Canada, and Australia. Clinical Infectious Diseases, 2012, 54, 111-118.	5.8	453
97	Risk of Anal Cancer in HIV-Infected and HIV-Uninfected Individuals in North America. Clinical Infectious Diseases, 2012, 54, 1026-1034.	0.6	55
98	Hepatitis C virus co-infection increases neurocognitive impairment severity and risk of death in treated HIV/AIDS. Journal of the Neurological Sciences, 2012, 312, 45-51.	4.4	25
99	Impact of current antiretroviral therapies on neuroAIDS. Expert Review of Anti-Infective Therapy, 2011, 9, 371-374.	3.0	7
100	Comparison of healthcare costs between local and immigrant HIV populations living in Southern Alberta, Canada. Health Policy, 2011, 103, 124-129.	3.3	43
101	HIV-1 viral diversity and its implications for viral load testing: review of current platforms. International Journal of Infectious Diseases, 2011, 15, e661-e670.	2.5	16
102	Survival Outcomes and Effect of Early vs. Deferred cART Among HIV-Infected Patients Diagnosed at the Time of an AIDS-Defining Event: A Cohort Analysis. PLoS ONE, 2011, 6, e26009.	2.1	9
103	Increasing HIV Subtype Diversity in Canadian-Born Patients Living in Southern Alberta, Canada. Journal of Acquired Immune Deficiency Syndromes (1999), 2011, 57, e27-e29.	2.1	15
104	Adverse Health Effects for Individuals Who Move Between HIV Care Centers. Journal of Acquired Immune Deficiency Syndromes (1999), 2011, 57, 51-54.	2.1	19
105	Comparative Effectiveness of Initial Antiretroviral Therapy Regimens. Journal of Acquired Immune Deficiency Syndromes (1999), 2011, 58, 253-260.	2.9	76
106	The persisting burden of invasive pneumococcal disease in HIV patients: an observational cohort study. BMC Infectious Diseases, 2011, 11, 314.	2.0	10
107	An avoidable transmission of HIV from mother to child. Cmaj, 2011, 183, 690-692.	3.9	53
108	Comparison of the RealTime HIV-1, COBAS TaqMan 48 v1.0, Easy Q v1.2, and Versant v3.0 assays for Determination of HIV-1 Viral Loads in a Cohort of Canadian Patients with Diverse HIV Subtype Infections. Journal of Clinical Microbiology, 2011, 49, 118-124.	3.4	9
109	Missing Data on the Estimation of the Prevalence of Accumulated Human Immunodeficiency Virus Drug Resistance in Patients Treated With Antiretroviral Drugs in North America. American Journal of Epidemiology, 2011, 174, 727-735.		

#	ARTICLE	IF	CITATIONS
109	Inflammation and epithelial cell injury in AIDS enteropathy: involvement of endoplasmic reticulum stress. <i>FASEB Journal</i> , 2011, 25, 2211-2220.	0.5	37
110	Risk Factors for Tuberculosis After Highly Active Antiretroviral Therapy Initiation in the United States and Canada: Implications for Tuberculosis Screening. <i>Journal of Infectious Diseases</i> , 2011, 204, 893-901.	4.0	33
111	Virologic and immunologic response to HAART, by age and regimen class. <i>Aids</i> , 2010, 24, 2469-2479.	2.2	92
112	LIMITATIONS OF OPT-OUT HIV SCREENING AND MOTHER-TO-CHILD HIV TRANSMISSION. <i>American Journal of Public Health</i> , 2010, 100, 388-389.	2.7	3
113	Z-FA-FMK as a novel potent inhibitor of reovirus pathogenesis and oncolysis <i>in vivo</i> . <i>Antiviral Therapy</i> , 2010, 15, 897-905.	1.0	12
114	Clinical outcomes and immune benefits of anti-epileptic drug therapy in HIV/AIDS. <i>BMC Neurology</i> , 2010, 10, 44.	1.8	15
115	Higher levels of Zidovudine resistant HIV in the colon compared to blood and other gastrointestinal compartments in HIV infection. <i>Retrovirology</i> , 2010, 7, 74.	2.0	16
116	CD4 count at presentation for HIV care in the United States and Canada: Are those over 50 years more likely to have a delayed presentation?. <i>AIDS Research and Therapy</i> , 2010, 7, 45.	1.7	73
117	Domestic Violence Screening: Prevalence and Outcomes in a Canadian HIV Population. <i>AIDS Patient Care and STDs</i> , 2010, 24, 763-770.	2.5	47
118	Late Presentation for Human Immunodeficiency Virus Care in the United States and Canada. <i>Clinical Infectious Diseases</i> , 2010, 50, 1512-1520.	5.8	187
119	Trends in Multidrug Treatment Failure and Subsequent Mortality among Antiretroviral Therapy-Experienced Patients with HIV Infection in North America. <i>Clinical Infectious Diseases</i> , 2009, 49, 1582-1590.	5.8	55
120	The five-year impact of an evolving global epidemic, changing migration patterns, and policy changes in a regional Canadian HIV population. <i>Health Policy</i> , 2009, 90, 296-302.	3.0	25
121	Effect of Early versus Deferred Antiretroviral Therapy for HIV on Survival. <i>New England Journal of Medicine</i> , 2009, 360, 1815-1826.	27.0	986
122	Risk factors for treatment-limiting toxicities in patients starting nevirapine-containing antiretroviral therapy. <i>Aids</i> , 2009, 23, 1689-1699.	2.2	69
123	HIV Infection of the Central Nervous System: Clinical Features and Neuropathogenesis. <i>Neurologic Clinics</i> , 2008, 26, 799-819.	1.8	127
124	Participation in HIV Research: The Importance of Clinic Contact Factors. <i>AIDS Patient Care and STDs</i> , 2008, 22, 619-625.	2.5	9
125	Discrepancies in Assignment of Subtype/Recombinant Forms by Genotyping Programs for HIV Type 1 Drug Resistance Testing May Falsely Predict Superinfection. <i>AIDS Research and Human Retroviruses</i> , 2008, 24, 995-1002.	1.1	11
126	Changing Epidemiology and Risk Factors for Gastrointestinal Non-Hodgkin's Lymphoma in a North American Population: Population-Based Study. <i>American Journal of Gastroenterology</i> , 2008, 103, 1762-1769.	0.4	48

#	ARTICLE	IF	CITATIONS
127	Does short-term virologic failure translate to clinical events in antiretroviral-naïve patients initiating antiretroviral therapy in clinical practice?. <i>Aids</i> , 2008, 22, 2481-2492.	2.2	18
128	Patients presenting with AIDS in the HAART era: a collaborative cohort analysis. <i>Aids</i> , 2008, 22, 2461-2469.	2.2	51
129	A potentially preventable case of serious influenza infection in a pregnant patient. <i>Cmaj</i> , 2007, 177, 851-853.	2.0	16
130	The oncology impact of highly active antiretroviral therapy. <i>Journal of Oncology Pharmacy Practice</i> , 2007, 13, 17-25.	0.9	1
131	Similar Challenges with Retention in Care Issues. <i>Clinical Infectious Diseases</i> , 2007, 45, 1527-1527.	5.8	5
132	Cohort Profile: The North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD). <i>International Journal of Epidemiology</i> , 2007, 36, 294-301.	1.9	176
133	Cytotoxic CD4+ T cells use granulysin to kill <i>Cryptococcus neoformans</i> , and activation of this pathway is defective in HIV patients. <i>Blood</i> , 2007, 109, 2049-2057.	1.4	79
134	Functional relevance of nonsynonymous mutations in the HIV-1 tat gene within an epidemiologically-linked transmission cohort. <i>Virology Journal</i> , 2007, 4, 107.	3.4	2
135	Short Communication: Identification of a Novel HIV Type 1 Subtype H/J Recombinant in Canada with Discordant HIV Viral Load (RNA) Values in Three Different Commercial Assays. <i>AIDS Research and Human Retroviruses</i> , 2007, 23, 1309-1313.	1.1	19
136	Compartmentalization of the gut viral reservoir in HIV-1 infected patients. <i>Retrovirology</i> , 2007, 4, 87.	2.0	106
137	Changes Over Time in Risk of Initial Virological Failure of Combination Antiretroviral Therapy. <i>Archives of Internal Medicine</i> , 2006, 166, 521.	3.8	77
138	Costing implications of recent treatment interruption studies. <i>Aids</i> , 2006, 20, 2239-2240.	2.2	1
139	Sensory neuropathy in human immunodeficiency virus/acquired immunodeficiency syndrome patients: Protease inhibitor-mediated neurotoxicity. <i>Annals of Neurology</i> , 2006, 59, 816-824.	5.3	131
140	Neuropsychiatric disorders in HIV infection: impact of diagnosis on economic costs of care. <i>Aids</i> , 2006, 20, 2005-2009.	2.2	20
141	Cytomegalovirus Disease in HIV Infection: Twenty Years of a Regional Population's Experience. <i>Clinical Infectious Diseases</i> , 2006, 42, 1808-1809.	5.8	11
142	Full-Length HIV Type 1 Genome Analysis Showing Evidence for HIV Type 1 Transmission from a Nonprogressor to Two Recipients Who Progressed to AIDS. <i>AIDS Research and Human Retroviruses</i> , 2005, 21, 575-579.	1.1	15
143	Role of viral evolutionary rate in HIV-1 disease progression in a linked cohort. <i>Retrovirology</i> , 2005, 2, 41.	2.0	22
144	Impact of Practice Changes on an Antiretroviral Budget in an HIV Care Program. <i>Disease Management and Health Outcomes</i> , 2005, 13, 209-217.	0.4	9

#	ARTICLE	IF	CITATIONS
145	Human immunodeficiency virus type 1 Nef protein mediates neural cell death: a neurotoxic role for IP-10. <i>Virology</i> , 2004, 329, 302-318.	2.4	158
146	Predictors of trend in CD4-positive T-cell count and mortality among HIV-1-infected individuals with virological failure to all three antiretroviral-drug classes. <i>Lancet, The</i> , 2004, 364, 51-62.	13.7	303
147	Growth hormone prevents human immunodeficiency virus-induced neuronal p53 expression. <i>Annals of Neurology</i> , 2003, 54, 605-614.	5.3	60
148	HIV dementia patients exhibit reduced viral neutralization and increased envelope sequence diversity in blood and brain. <i>Aids</i> , 2002, 16, 1905-1914.	2.2	39
149	Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. <i>Lancet, The</i> , 2002, 360, 119-129.	13.7	1,415
150	Canadian Expert Panel Recommendations on the Management of CNS Symptoms Related to Efavirenz. <i>Canadian Journal of Infectious Diseases & Medical Microbiology</i> , 2001, 12, 20C-30C.	0.3	4
151	Accelerated replicative senescence of the peripheral immune system induced by HIV infection. <i>Aids</i> , 2000, 14, 771-780.	2.2	75
152	Antiretroviral Medication Adherence and Persistence with Respect to Adherence Tool Usage. <i>AIDS Patient Care and STDs</i> , 2000, 14, 351-358.	2.5	25
153	The costs of antiretroviral drug wastage. <i>Aids</i> , 2000, 14, 616-617.	2.2	2
154	Efavirenz dosing in patients receiving continuous ambulatory peritoneal dialysis. <i>Aids</i> , 2000, 14, 1062.	2.2	13
155	The Use of Antiretroviral Agents in Patients with Renal Insufficiency. <i>AIDS Patient Care and STDs</i> , 1999, 13, 517-526.	2.5	5
156	Pooch protease paunch. <i>Lancet, The</i> , 1999, 353, 2078.	13.7	0
157	Predictors of survival and eradication of <i>Mycobacterium avium</i> complex bacteremia (MAC) in AIDS patients in the Canadian Randomized MAC Treatment Trial. <i>Aids</i> , 1999, 13, 575-582.	2.2	5
158	Avascular necrosis in HIV infection. <i>Aids</i> , 1999, 13, 1997.	2.2	25
159	Does In Vitro Susceptibility to Rifabutin and Ethambutol Predict the Response to Treatment of <i>Mycobacterium avium</i> Complex Bacteremia with Rifabutin, Ethambutol, and Clarithromycin?. <i>Clinical Infectious Diseases</i> , 1998, 27, 1401-1405.	5.8	25
160	Active Immunization of Patients with HIV Infection: A Study of the Effect of VaxSyn, a Recombinant HIV Envelope Subunit Vaccine, on Progression of Immunodeficiency. <i>AIDS Research and Human Retroviruses</i> , 1998, 14, 483-490.	1.1	37
161	Predictors of a viral response and subsequent virological treatment failure in patients with HIV starting a protease inhibitor. <i>Aids</i> , 1998, 12, 2161-2167.	2.2	142
162	Activity of the soft gelatin formulation of saquinavir in combination therapy in antiretroviral-naïve patients. <i>Aids</i> , 1998, 12, F103-F109.	2.2	45

#	ARTICLE	IF	CITATIONS
163	Seroprevalence of Cytomegalovirus, Toxoplasma gondii, Syphilis, and Hepatitis B and C Virus Infections in a Regional Population Seropositive for HIV Infection. Canadian Journal of Infectious Diseases & Medical Microbiology, 1998, 9, 209-214.	0.3	5
164	Improved Survival and Reduced Clinical Progression in HIV-Infected Patients with Advanced Disease Treated with Saquinavir plus Zalcitabine. Antiviral Therapy, 1998, 3, 33-42.	1.0	14
165	HIV-Related Non-Hodgkin's Lymphoma in Calgary. Canadian Journal of Infectious Diseases & Medical Microbiology, 1996, 7, 115-120.	0.3	1
166	A Comparison of Two Regimens for the Treatment of Mycobacterium avium Complex Bacteremia in AIDS: Rifabutin, Ethambutol, and Clarithromycin versus Rifampin, Ethambutol, Clofazimine, and Ciprofloxacin. New England Journal of Medicine, 1996, 335, 377-384.	27.0	304
167	Lymphocyte Membrane Modifications Induced by HIV Infection.. Tohoku Journal of Experimental Medicine, 1994, 173, 115-131.	1.2	10
168	Absence of an Association Between Enteric Parasites in the Manifestations and Pathogenesis of HIV Enteropathy in Gay Men. Scandinavian Journal of Infectious Diseases, 1992, 24, 567-575.	1.5	18
169	Gastrointestinal tissue cultures for HIV in HIV-infected/AIDS patients. Aids, 1992, 6, 553-556.	2.2	28
170	Rhodococcus equi "An easily missed opportunistic pathogen. Scandinavian Journal of Infectious Diseases, 1991, 23, 1-6.	1.5	43
171	Neurotoxicity of acyclovir in end stage renal disease. Journal of Antimicrobial Chemotherapy, 1990, 25, 300-300.	3.0	18
172	Herpes simplex virus infection of the hand. Journal of the American Academy of Dermatology, 1990, 22, 111-116.	1.2	35
173	Childhood Lymphadenitis in a Harsh Northern Climate due to Atypical Mycobacteria. Scandinavian Journal of Infectious Diseases, 1987, 19, 77-83.	1.5	12
174	Effect of acyclovir on the uptake of ¹³¹ I-labelled 1-(2-fluoro-2-deoxy- ¹²⁵ I-D-arabinofuranosyl)-5-iodouracil in herpes infected cells. Journal of Medical Virology, 1987, 22, 183-188.	5.0	7